Previous studies have illustrated the different uptake and retention profiles of 177Lu-octreotate and 177Lu-octreotide and their different therapeutic effects in mice with human small-cell lung cancer and/or the GOT1 NET [29,30]. This evidence concerns the gene GOT1 and small cell lung carcinoma.